Overactive Bladder Diagnoses Increased After Guideline Publication
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 4, 2024 -- An increase in overactive bladder (OAB) diagnoses was seen following publication of the first OAB guideline, and the rate of third-line therapy procedures also increased, according to a study published online Nov. 19 in Neurourology & Urodynamics.
Hodan Mohamud, from the University of Toronto, and colleagues conducted a retrospective cohort study to examine trends in therapy utilization before and after the 2014 American Urological Association/Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction OAB guideline amendment and publication of a clinical care pathway in 2016. Patterns of care were assessed from 2013 to 2018.
The study included 1,825,782 patients (mean age, 61.1 ± 16.7 years). From 2013 to 2017, the researchers found a 369 percent increase in the number of new OAB diagnoses. Nineteen percent of patients were treated with oral and/or third-line therapies during the six-year study period. The number of oral medications prescribed peaked in 2016, then decreased 17 percent by 2018. The two most prescribed oral medications in 2013 were oxybutynin and solifenacin (46.0 and 31.8 percent, respectively). Mirabegron surpassed solifenacin by 2018 (18.5 versus 16.5 percent), while oxybutynin still accounted for most prescriptions (55 percent). Patients older than 65 years of age filled 80 percent of all initial mirabegron prescriptions. From 2013 to 2018, the rate of third-line therapy procedures nearly doubled (nine to 17 per 1,000 OAB patients).
"These trends suggest that OAB therapy guidelines and clinical practice pathways may influence treatment patterns," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Hormone Therapy Tied to Worse Bladder Health in Postmenopausal Women
TUESDAY, May 6, 2025 -- Hormone therapy use is linked to worse bladder health in postmenopausal women, according to a study published online April 29 in Menopause. Camille...
Transurethral Fulguration Alleviates Pelvic Pain in Interstitial Cystitis
MONDAY, May 5, 2025 -- For patients with interstitial cystitis (IC), transurethral fulguration (TUF) is effective for alleviating pelvic pain, according to a study published...
ACP: AI Recommendations More Often Better Quality for Virtual Care Visits
MONDAY, April 7, 2025 -- Artificial intelligence (AI) recommendations are more often rated as better quality than final recommendations of physicians for virtual care visits made...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.